(thirdQuint)SPIRIT II: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System.

 The SPIRIT II trial was a randomized, single blind, active control, multi-center clinical evaluation.

 Subject eligibility criteria were similar to SPIRIT III and enrollment duration overlapped between studies.

 In this study, 300 subjects (3:1 randomization XIENCE V(R) EECSS: TAXUS cent PECSS were enrolled at 31 sites outside the United States.

 The primary endpoint was in-stent late loss at 6 months.

 Secondary endpoints included clinical outcomes at months 1, 6, and 9 months and 1, 2, 3, 4 and 5 years; angiographic results at 6 months and 2 years; and IVUS results at 6 months and 2 years.

 Follow-up through 3 years is currently available.

.

 SPIRIT II: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System@highlight

Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V(R) Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS cent EXPRESS2 cent Paclitaxel Eluting Coronary Stent System.

 TAXUS cent EXPRESS2 cent Paclitaxel Eluting Coronary Stent System is manufactured by Boston Scientific.

